Navigation Links
Redsense Medical Receives FDA Clearance for the Redsense Safety Device for Home/Self use During Home Hemodialysis
Date:5/18/2010

HALMSTAD, Sweden, May 18, 2010 /PRNewswire/ --

- With Photo

The Redsense safety device is now cleared by FDA for Home/Self use and is consequently available to all patients with home hemodialysis in the US. Redsense safety device is designed to detect venous needle dislodgement during hemodialysis and its use has already improved in-clinic patient safety. Optimizing safety conditions for home hemodialysis users is a core ambition for Redsense Medical.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100518/391613 )

Dialysis equipment today is required to have a system which protects the patient from blood loss due to dislodgement of the venous needle. The commonly accepted solution is to monitor by the venous pressure alarm but a better solution has long been requested. Even with the routine supervision of medical staff still the venous needle can become dislodged: the dialysis machine will then continue to draw blood from the patient's artery however not returning blood in the loop circuit as the venous needle has become dislodged and the patient's blood ends up elsewhere. If undetected, this blood loss can have very serious consequences in only a few minutes. Redsense safety device provides a solution to this problem and detects venous needle dislodgement instantaneously; it only takes a few millilitres of blood on the sensor patch to sound the alarm.

It is well known that home hemodialysis allows for daily treatments, improving quality of life, morbidity and life expectancy. Home hemodialysis is also more cost-effective as it can free hospital beds and reduces the transport costs related to centralized dialysis care.

Being able to address the market for home hemodialysis is an important step according to, CEO Patrik Byhmer:

    - This is where Redsense really can make a difference. It's very
      satisfying being able to increase the level of safety among the users
      of home hemodialysis.

The company

Redsense Medical has offices in Sweden and in the U.S. (Chicago, IL). For more information: http://www.redsensemedical.com.

The product

The Redsense safety device is the results of close co-operation between medical staff and engineers. Redsense consists of two parts: a sensor patch and an alarm unit. An infrared signal is transmitted from the alarm unit to the sensor patch using fibre optic cable. In the event of bleeding, inner layers of the patch smear blood over the optical sensor, which triggers the alarm.


'/>"/>
SOURCE Redsense Medical AB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ultra-Fine Metal Tubing Smoothes the Way for Miniaturized Medical Devices
2. Elekta / Mitsubishi Electric Collaboration Helps Japans Gunma University Heavy Ion Medical Center Launch Advanced Carbon Ion Therapy for Treating Cancer
3. TriReme Medical, Inc. Receives FDA 510(k) Clearance for a Broad Matrix of GliderXtreme(TM) PTA Balloon Catheter Sizes
4. China Sky One Medical Provides Sales Forecast for 13 New Products
5. China Sky One Medical Attended Import and Export Fair to Enhance International Growth Opportunity
6. Winner Medical Reports Second Quarter Results for the Fiscal Year 2010
7. China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call
8. China Sky One Medical Announces Conference Call to Discuss First Quarter 2010 Results
9. PolyTouch Medical Ltd. Announces the Submission of a Premarket Application for PatchAssist - an Innovative Mesh Deployment and Placement Device for Laparoscopic Hernia Repair
10. BioMS Medical updates University of Alberta equity position
11. InterTech Service to Counter Widely Reported Problems in Automotive, Medical Device and Other Industries Requiring Rigorous Quality Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
Breaking Biology News(10 mins):